The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral
injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the
skin, to understand what the body does to the PH-762, and to observe how the tumor responds
to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a
single tumor, followed by surgical removal of the tumor approximately two weeks later.